Gate Bioscience Expands Collaboration and License Agreement with Lilly to Target Difficult-to-Drug ProteinsMulti-year expansion of the companies’ 2025 agreement to use Gate’s Molecular Gate drug discovery engine to design molecular gate medicines for Lilly targets
Gate Bioscience Appoints Industry Veteran Jeff Hatfield to Board of Directors
Gate Bioscience, a biotechnology company developing a new class of small molecule medicines to eliminate disease-causing proteins at their source, today announced the appointment of Jeff Hatfield to its Board of Directors. Mr. Hatfield brings more than three decades of successful industry leadership across biotech and pharmaceuticals.
